ProCE Banner Activity

Promising Strategies on the Horizon for HR+/HER2- MBC

Slideset Download
Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including what to do after progression on a CDK4/6 inhibitor and a review of novel agents in the setting of resistance to standard-of-care therapies.

Released: May 31, 2019

Expiration: May 29, 2020

No longer available for credit.

Share

Faculty

Adam M. Brufsky

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Supporters

Lilly

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Adam M. Brufsky, MD, PhD

Associate Professor
Department of Medicine, Division of Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania